CareDx, Inc.
CDNAHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, CareDx, Inc. focuses on Diagnostics & Research services and products. CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. With a market capitalization of $1.14B, it sits in small-cap territory. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Market Cap
$1.14B
Beta
2.49
P/E (TTM)
—
P/E (Fwd)
19.46
EPS (TTM)
$-0.16
EPS (Fwd)
$1.13
ROE
-2.4%
ROA
-1.8%
Cash
$187.2M
Total Debt
$24.5M
Free CF
$70.1M
52W Change
14.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $187.2M in cash comfortably exceeding the $24.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $70.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -2.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $321.8M to $379.8M.
CareDx, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CareDx, Inc. and its sector.